- Home
- SAR vs VRCA Comparison
SAR vs VRCA Comparison
Compare SAR & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAR
- VRCA
- Stock Information
- Founded
- SAR 2007
- VRCA 2013
- Country
- SAR United States
- VRCA United States
- Employees
- SAR N/A
- VRCA N/A
- Industry
- SAR Investment Managers
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- SAR Finance
- VRCA Health Care
- Exchange
- SAR Nasdaq
- VRCA Nasdaq
- Market Cap
- SAR 331.7M
- VRCA 363.1M
- IPO Year
- SAR 2007
- VRCA 2018
- Fundamental
- Price
- SAR $23.78
- VRCA $0.69
- Analyst Decision
- SAR Buy
- VRCA Hold
- Analyst Count
- SAR 4
- VRCA 5
- Target Price
- SAR $25.42
- VRCA $6.00
- AVG Volume (30 Days)
- SAR 136.1K
- VRCA 749.9K
- Earning Date
- SAR 01-08-2025
- VRCA 11-04-2024
- Dividend Yield
- SAR 12.43%
- VRCA N/A
- EPS Growth
- SAR N/A
- VRCA N/A
- EPS
- SAR 1.57
- VRCA N/A
- Revenue
- SAR $155,255,243.00
- VRCA $9,210,000.00
- Revenue This Year
- SAR $5.75
- VRCA $54.16
- Revenue Next Year
- SAR N/A
- VRCA $99.78
- P/E Ratio
- SAR $15.15
- VRCA N/A
- Revenue Growth
- SAR 20.62
- VRCA 187.45
- 52 Week Low
- SAR $21.56
- VRCA $0.61
- 52 Week High
- SAR $26.49
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- SAR 39.96
- VRCA 33.00
- Support Level
- SAR $23.00
- VRCA $0.61
- Resistance Level
- SAR $24.36
- VRCA $1.32
- Average True Range (ATR)
- SAR 0.49
- VRCA 0.11
- MACD
- SAR -0.12
- VRCA -0.02
- Stochastic Oscillator
- SAR 27.37
- VRCA 12.08
About SAR Saratoga Investment Corp New
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests primarily in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.